New pill tested for common arthritis types
NCT ID NCT06628206
Summary
This early-stage study is testing the safety and tolerability of a new oral drug called LPX-TI641 in people with rheumatoid arthritis or psoriatic arthritis. About 48 participants will take the drug or a placebo pill daily for 28 days. The main goal is to see how well the drug is tolerated and how the body processes it, not to measure its effectiveness against arthritis symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITINGAmman, ST B204, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.